May 20th is a special date – International Clinical Trials Day reminds us all of the vital role our everyday work plays in advancing modern medicine. It’s a moment to pause and reflect on the impact we’re making together: breakthrough therapies, improved Patient care, and real progress in quality of life.

This year’s celebration coincides with the international awareness campaign “Health has a future in clinical trials. Become the Patient of Tomorrow!” launched by Pratia in Poland in 2024. The campaign is expanding rapidly, and as of today, it has reached 8 countries across our global network. The campaign aims to raise public awareness about clinical trials, dispel myths, and highlight their true value—not only for individual patients but for the healthcare system as a whole.

Still, based on four blended survey reports “Opinions on Clinical Trials” conducted by Pratia in Poland, Bulgaria, Ukraine, and Czechia, over 40% of respondents admit they have little knowledge about them. This gap is a challenge—but also an opportunity. As professionals, we are in a unique position to close it with trusted information, empathy, and continued commitment.

Clinical research is more than procedures and protocols. It's about relationships, trust, and progress. As Pratia physicians emphasize, trials offer access to cutting-edge therapies not yet available in standard care, advanced diagnostics, and personalized support. Every participant has a story—often one of a chance for significant life improvement.

On this day, we want to thank all of you—investigators, study coordinators, recruitment teams, operations staff, lab specialists, QA professionals, CRAs, and everyone contributing to the world of clinical research. Thanks to your efforts, the Patients of Tomorrow are not just part of a campaign—they are living proof of how we’re changing medicine for the better.

Thank you for helping to drive this transformation forward. Together, we shape the future of medicine—starting today.Join the celebration – explore our Patients’ real stories and more below.

Each country-specific site offers locally tailored content in multiple languages. Topics range from “How Clinical Trials Work” and “Frequently Asked Questions” to interviews with healthcare professionals and up-to-date listings of open Clinical Trials.

May marks National Cancer Research Month and National Cancer Awareness Month in the U.S.—a time to reflect, recognize, and recommit.

At Kapadi, this month resonates deeply with our mission. We join the global community in honoring the scientists, clinicians, advocates, and survivors who have driven extraordinary progress in cancer research. Thanks to their work, over 18 million people in the U.S. are living with, through, and beyond cancer—and millions more around the world are finding new hope each year.

This year’s theme, “United by Cancer Research: One Mission. One Voice,” reminds us that meaningful progress happens when we come together across disciplines, borders, and experiences. While survival rates are improving and innovations in treatment are transforming lives, challenges remain—especially in addressing disparities and ensuring breakthroughs reach everyone who needs them.

We are proud to be part of that global effort. As a leading global oncology CRO, Kapadi specializes in advancing oncology and cell & gene therapies from concept to clinic. Our work in complex trials is powered by our team’s deep expertise, cutting-edge technology, and strong site relationships worldwide.

We're also looking forward to contributing to key industry conversations at ASGCT 2025 and ASCO 2025, where we’ll connect with peers, share insights, and continue driving the future of cancer care forward.

To all at Kapadi: your dedication is part of this bigger mission. Let’s keep pushing boundaries—together.

We still can’t get over the fact that 𝗶𝗻 𝗪𝗮𝘀𝗵𝗶𝗻𝗴𝘁𝗼𝗻, 𝗗.𝗖., 𝗣𝗿𝗮𝘁𝗶𝗮 𝘄𝗮𝘀 𝗻𝗮𝗺𝗲𝗱 𝗕𝗲𝘀𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗡𝗲𝘁𝘄𝗼𝗿𝗸 𝗮𝘁 𝘁𝗵𝗲 𝗩𝗜𝗘 𝗔𝘄𝗮𝗿𝗱𝘀, held during The World Vaccine Congress.

This award celebrates organizations that “support multiple and diverse clinical phase and outcomes trials for vaccines… introduce new services… and demonstrate rapid enrollment and outstanding study subject retention.”

It’s an honor to be recognized for our efforts to match complex clinical development needs with consistent delivery across our global network of Research Sites.

👏🏼Congratulations to 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗮𝘁 𝗣𝗿𝗮𝘁𝗶𝗮: from Feasibility and Study Operations to our Investigators and the Patients who trust us with their care. 𝗧𝗵𝗶𝘀 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁 𝗶𝘀 𝘀𝗵𝗮𝗿𝗲𝗱 𝗯𝘆 all of us!

We are proud to announce that our abstract, titled “AI-driven integration of microbiome and exosome profiles for precision diagnostics and therapeutics in colorectal cancer,” has been accepted for presentation by both the American Society of Clinical Oncology (ASCO) and the American Society of Gene & Cell Therapy (ASGCT).

This dual recognition by two of the world’s leading scientific organizations reflects the groundbreaking nature of our work and the dedication of our entire team. Our research highlights the innovative application of artificial intelligence to integrate complex biological data, offering new pathways for precision diagnostics and personalized treatment in colorectal cancer.

Congratulations to Emile Youssef, Daniel Kowalski, Brandon Fletcher and Dannelle Palmer, who authored this paper, for this achievement! We look forward to sharing our findings with the global scientific community and continuing to push the boundaries of medical research together.

You can find the full abstract here:

On the occasion of Earth Day, our colleagues from Toruń, Poland, took the initiative to organize a local clean-up campaign. The team came together to collect litter from the streets around our headquarters and other parts of the city, showing what it means to care for both our local environment and our global impact.

So far, two teams have already taken part—and four more are getting ready to join in!

One participant summed it up perfectly:

“7 full bags of trash, lots of great conversations, and plenty of laughter. 🙂 We know this was our first clean-up event, but definitely not our last! ;)”

Let’s keep the momentum going—no matter where you are in the world, consider organizing a clean-up with your local team. It’s a great way to connect, contribute, and take pride in making a visible difference.

If you do, be sure to share photos and stories—we’d love to see your impact!

Starting December 1st, the method of logging into NEUCAnet will change.

Below is the information about the planned changes:

Web address

The web address will remain the same: https://neucanet.neuca.pl

The login site

Below, you can find screenshots of the updated login page to guide you through the process:

Password

Password will not change. The password you are currently using will continue to work after December 1st.

Current login format: neuca/username (example: neuca/jdoe)

New login format (effective December 1st):

username@company.com

Examples:

jdoe@humaneva.com

jdoe@kapadi.com

jdoe@agaticlinical.com

jdoe@pratia.com

jdoe@hyggio.com

jdoe@neuca.com

For employees with a business email address:

After November 27th, you will receive an automatic email with information about your new login.

For employees without a business email address:

After November 27th, your manager will receive a list with your login details.

Need help?

If you encounter any difficulties logging in after December 1st, please reach out to your local HR representative or contact the IT Support / Service Desk.

This initiative is designed to support oncology Patients and their loved ones in finding Clinical Trials. Through the OncoInformer, Patients not only receive assistance in locating innovative therapies but also compassionate support from our dedicated Team of specialists.

Why did we create the OncoInformer?

Many Patients are unsure where to look for available therapies or find it difficult to navigate complex medical terminology and search tools. We aim to provide them with easier access to cutting-edge treatments. We've noticed that many Patients need guidance when exploring the world of Clinical Trials, and the OncoInformer was created to fulfill that need.

How does the service work?

Through the OncoInformer, our team helps locate potential Clinical Trials both within Pratia Sites and other institutions. Patients and their families can reach us by completing a contact form on our website at pratia.pl/onkoinformator. After submitting the form, our Call Center contacts Patient within 72 hours. Additionally, Patients can directly call our helpline, available Monday to Friday from 8 AM to 8 PM. Please note that the OncoInformer service is available only in Poland and is entirely free of charge.

Our mission is to make it easier for Patients in Poland to access the latest therapies available through Clinical Trials. We are here to support them and their families every step of the way in finding the right Clinical Trial. To date, over 100 Patients have already benefited from the OncoInformer.

As we approach the 10-year mark since we began our journey in clinical trials alongside the Neuca Group, I find myself reflecting on how far we've come. Many of us started this journey together as the first employees, beginning with just a small segment of what has now become one of the largest integrated clinical research platforms in Europe and one of the few of its kind in the world. With the tremendous support of both the NEUCA and Humaneva Group Teams, we have built an organization that has a real, tangible impact on human lives.

But as you all know, the research and life science industry is tough, never sleeps, and constantly evolves. If we want to continue our mission of improving patients' lives through clinical research, we must keep moving forward. We need to expand our platform to reach every patient in the world. The market is aggressive, and we can't achieve this alone—not even with the support of our wonderful parent company, Neuca Group. This is why we have decided to bring in a strategic partner, a minority investor, to support our endeavors.

I am thrilled to announce that Humaneva Inc., our holding company registered in Delaware, which includes Kapadi, Pratia, Hyggio, and their related subsidiaries, along with the NEUCA Board of Directors, has successfully closed a deal with Viking Global Investors, one of the largest hedge funds in the world. Viking, managing over $50 billion in assets, has acquired a minority stake in Humaneva Inc. for $50 million. Furthermore, Viking has been granted a one-year option to invest an additional $50 million in Humaneva Inc., reinforcing our growth strategy and commitment to innovation.

This partnership is not just about money; it's about fulfilling our dreams and meeting our patients' needs and hopes. This is how we can make a true global impact on people's lives and our future generations.

I would like to express my deepest gratitude to all of you. Each of you has played a crucial role in keeping this organization in the best shape ever, and this investment is clear evidence that you have done an outstanding job. Many of you have been with us almost since the beginning, and the same goes for our colleagues from the companies we have acquired over time. You are the ones who have made the difference and transformed our organization to reach this milestone.

I also want to extend my heartfelt thanks to the Neuca Shareholders, Board, and Central Teams who have supported this strategic and exceptional move within the group. They have taken significant risks, allowing us to grow and expand over the last 10 years in the very volatile life sciences industry. Without their support over the past decade, we would never have been able to achieve this milestone.

Looking ahead, nothing will change in our core mission. We will continue doing what we do best—bringing clinical research as a care option to our patients and supporting our sponsors in this endeavor. Humaneva will scale up and grow its operations in the countries where we are already present, maintaining our #1 position in each of them. We will also expand into new continents and countries, with a particular focus on the US and the APAC region for investments and M&A growth.

Thank you for your unwavering support and for being a part of this journey. Together, we will continue to make a profound impact on people's lives.

Tomek Dąbrowski, CEO HUMANEVA Inc.

LEARN ABOUT ITS PROVISIONS

We are implementing the policy throughout the NEUCA Group, including in the HUMANEVA Group's clinical trials segment for Pratia, Hyggio and Kapadi. In doing so, we are bringing our organization in line with the standards for reporting sustainability (ESG) issues.

We are obligated to do so by European Union law. The standards are mandatory for the NEUCA Group. The policy collects in a single document our commitments to respecting and upholding the human rights of employees, co-workers and contractors.

Below are some of them:

❌ We do not accept or condone any form of forced labor or child labor,

✅ We create safe working conditions,

✅ We fight corruption and bribery,

The rules contained in the Policy are not new. They are based on our organization's applicable regulations, values and commitments enshrined in, among others,

☑️ Group Code of Conduct,

☑️ Responsible Business Strategy,

☑️ Anti-Corruption Code,

☑️ Set of Rules of Conduct for Suppliers and Subcontractors of the NEUCA Group.

The policy sets a global standard for human rights conduct throughout our organization. Familiarize yourself with its contents.